WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective PPARα agonist with an IC₅₀ of 10.11 μM for human PPARα, validated as a tool for metabolic disorder and inflammation studies (APExBIO). Dual PPARα/γ modulation is achieved via aliphatic α-substitution, enhancing efficacy in the lower micromolar range (APExBIO). WY-14643 down-regulates VCAM-1 and monocyte adhesion in endothelial cells, confirming anti-inflammatory properties at 250 μM in vitro (Linoleic acid–PPARα study). Oral administration in rats (3 mg/kg/day, 2 weeks) reduces plasma glucose, triglycerides, and liver fat, and improves insulin sensitivity without increasing body weight (APExBIO). The compound is supplied by APExBIO for research use only and is insoluble in water but highly soluble in DMSO and ethanol under defined conditions (APExBIO).

Biological Rationale

Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that regulates lipid metabolism, inflammation, and energy homeostasis (Bao et al., 2025). Activation of PPARα modulates transcription of genes involved in fatty acid oxidation, triglyceride clearance, and inflammatory response. Dysregulation of PPARα signaling is implicated in metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), diabetes, and atherosclerosis. WY-14643 (Pirinixic Acid) serves as a standard reference compound due to its high selectivity and potency for PPARα. Its use enables precise dissection of PPAR-driven pathways in disease models. Recent multi-omics studies have also identified PPARα's role in tumor microenvironment modulation, notably in primary pulmonary lymphoepithelioma-like carcinoma (pLELC), where PPARα upregulates tissue factor (TF), influencing tumor progression (Bao et al., 2025).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 is a synthetic ligand that binds and activates PPARα with an IC₅₀ of 10.11 μM for the human isoform (APExBIO). Upon binding, PPARα forms a heterodimer with retinoid X receptor (RXR), which interacts with peroxisome proliferator response elements (PPREs) in the promoter regions of target genes. This mechanism upregulates gene expression involved in fatty acid uptake, mitochondrial β-oxidation, and lipoprotein metabolism. WY-14643 can also indirectly modulate inflammation by reducing adhesive and inflammatory molecule expression, such as VCAM-1, through PPARα-dependent transcriptional repression in endothelial cells.
Aliphatic α-substitution of WY-14643 increases its affinity for both PPARα and PPARγ, producing balanced dual agonists in the lower micromolar range (APExBIO). This dual action is relevant for addressing complex metabolic phenotypes involving both lipid and glucose dysregulation.

Evidence & Benchmarks

• WY-14643 activates human PPARα with an IC₅₀ of 10.11 μM, confirming high potency and selectivity (APExBIO).
• 250 μM WY-14643 pretreatment down-regulates TNF-α-induced VCAM-1 expression and monocyte adhesion in endothelial cells, demonstrating anti-inflammatory effects (Bao et al., 2025).
• Oral WY-14643 at 3 mg/kg/day for 2 weeks in high fat-fed rats lowers plasma glucose, triglycerides, leptin, muscle triglycerides, and long-chain acyl-CoAs, reduces visceral fat and hepatic triglyceride content, and enhances insulin sensitivity without increasing body weight (APExBIO).
• Aliphatic α-substitution on WY-14643 increases dual activity at PPARα/γ, confirmed by in vitro binding and reporter assays at low micromolar concentrations (APExBIO).
• WY-14643 increases hepatic TNFα mRNA via Kupffer cell activation, indirectly promoting hepatocyte mitogenesis (APExBIO).
• PPARα activation by ligands such as WY-14643 upregulates tissue factor (TF) in pLELC, mediating tumor microenvironment changes (Bao et al., 2025).

For broader context, see this article, which focuses on immunometabolic mechanisms; this review extends it by providing atomic, quantitative benchmarks and new in vivo results. For unique insights into dual PPARα/γ agonism, compare with this piece, whereas the present article clarifies dosing and selectivity parameters.

Applications, Limits & Misconceptions

WY-14643 is widely used in:

• Metabolic disorder research: NAFLD, diabetes, dyslipidemia, and insulin resistance models.
• Inflammation studies: Endothelial, hepatic, and adipose tissue inflammation.
• Tumor microenvironment modulation: Mechanistic studies of PPARα’s influence on tumor progression and immune infiltration (Bao et al., 2025).
• PPAR signaling pathway mapping: Dissecting gene regulatory networks governing lipid metabolism and cellular energy homeostasis.

See this advanced review for in-depth tumor microenvironment perspectives, which this article updates with direct anti-inflammatory benchmarks.

Common Pitfalls or Misconceptions

• Not a medical or diagnostic agent: WY-14643 is for research use only and not approved for human or veterinary therapeutic use (APExBIO).
• Water insolubility: The compound is insoluble in water and should be dissolved in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL with ultrasonic assistance) for experimental use (APExBIO).
• Short-term solution stability: WY-14643 solutions are suitable for short-term use only; long-term storage is not recommended (APExBIO).
• Species differences: Potency and selectivity may vary between human and non-human PPAR isoforms.
• Misattribution of dual agonism: Dual PPARα/γ activity requires specific aliphatic α-substitution, not native WY-14643.

Workflow Integration & Parameters

WY-14643 is supplied as a solid for maximum stability. Dissolve in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic assistance recommended) for cell-based or in vivo studies. Store powder at -20°C in a desiccated environment. Prepare solutions immediately before use, as repeated freeze-thaw cycles are discouraged. For in vitro anti-inflammatory assays, a concentration of 250 μM effectively down-regulates VCAM-1 expression and monocyte adhesion in endothelial cells stimulated with TNF-α (Bao et al., 2025). In rodent metabolic studies, oral dosing at 3 mg/kg/day for 2 weeks is benchmarked for reduction of plasma glucose and triglycerides without increasing body weight (APExBIO). Always validate dosing and solvent compatibility for your specific model.

For translational perspectives and future strategies, see this expert review; this article adds current, quantitative usage parameters and addresses practical pitfalls.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) remains a gold-standard, selective PPARα agonist for metabolic and inflammation research. Its dual PPARα/γ agonist capacity, modulated by α-substitution, expands its utility in complex metabolic and tumor models. Recent evidence supports its role in modulating the tumor microenvironment via PPARα-dependent TF expression, opening translational research avenues (Bao et al., 2025). For detailed specifications and ordering, refer to the A4305 kit from APExBIO.